The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. [electronic resource]
Producer: 20111102Description: 1137-46 p. digitalISSN:- 1744-8042
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal -- therapeutic use
- Aryl Hydrocarbon Hydroxylases -- genetics
- Breast Neoplasms -- drug therapy
- Combined Modality Therapy
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 CYP2D6 -- genetics
- DNA, Neoplasm -- genetics
- Data Interpretation, Statistical
- Female
- Follow-Up Studies
- Genotype
- Humans
- Lymphatic Metastasis -- pathology
- Menopause
- Middle Aged
- Pharmacogenetics
- Predictive Value of Tests
- Prognosis
- Receptors, Progesterone -- metabolism
- Retrospective Studies
- Survival Analysis
- Tamoxifen -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.